DK2475362T3 - Cancerstamcellemålrettet og lægemiddelresistent cancerterapi - Google Patents

Cancerstamcellemålrettet og lægemiddelresistent cancerterapi Download PDF

Info

Publication number
DK2475362T3
DK2475362T3 DK10816100.1T DK10816100T DK2475362T3 DK 2475362 T3 DK2475362 T3 DK 2475362T3 DK 10816100 T DK10816100 T DK 10816100T DK 2475362 T3 DK2475362 T3 DK 2475362T3
Authority
DK
Denmark
Prior art keywords
cancer
pharmaceutical resistance
cleaned
template cleaned
template
Prior art date
Application number
DK10816100.1T
Other languages
English (en)
Inventor
Angelika Burger
Original Assignee
Kominox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox Inc filed Critical Kominox Inc
Application granted granted Critical
Publication of DK2475362T3 publication Critical patent/DK2475362T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK10816100.1T 2009-09-10 2010-09-09 Cancerstamcellemålrettet og lægemiddelresistent cancerterapi DK2475362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10
PCT/US2010/048308 WO2011031890A2 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Publications (1)

Publication Number Publication Date
DK2475362T3 true DK2475362T3 (da) 2019-06-03

Family

ID=43647965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10816100.1T DK2475362T3 (da) 2009-09-10 2010-09-09 Cancerstamcellemålrettet og lægemiddelresistent cancerterapi

Country Status (24)

Country Link
US (1) US20110059186A1 (da)
EP (1) EP2475362B1 (da)
JP (1) JP5710619B2 (da)
KR (2) KR20120061908A (da)
CN (2) CN107412771A (da)
AR (1) AR079000A1 (da)
AU (1) AU2010292192B2 (da)
BR (1) BR112012008315B1 (da)
CA (1) CA2772411C (da)
CY (1) CY1121973T1 (da)
DK (1) DK2475362T3 (da)
ES (1) ES2723778T3 (da)
HU (1) HUE043387T2 (da)
IN (1) IN2012DN02008A (da)
LT (1) LT2475362T (da)
MX (1) MX2012002855A (da)
PL (1) PL2475362T3 (da)
PT (1) PT2475362T (da)
RU (1) RU2568834C2 (da)
SG (2) SG179069A1 (da)
SI (1) SI2475362T1 (da)
TR (1) TR201905548T4 (da)
TW (1) TWI564012B (da)
WO (1) WO2011031890A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Ｈｒｐ-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
US20180036331A1 (en) * 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
WO2018217975A1 (en) * 2017-05-24 2018-11-29 The Regents Of The University Of California Antisense therapies for treating cancer
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
TR200002243T2 (tr) * 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
EP2477635A4 (en) * 2009-09-18 2013-03-27 Kominox Inc METHODS OF TREATING CEREBRAL TUMORS

Also Published As

Publication number Publication date
KR20150038702A (ko) 2015-04-08
KR20120061908A (ko) 2012-06-13
WO2011031890A3 (en) 2011-08-25
TWI564012B (zh) 2017-01-01
SG179069A1 (en) 2012-04-27
IN2012DN02008A (da) 2015-07-24
BR112012008315B1 (pt) 2021-08-03
SI2475362T1 (sl) 2019-08-30
RU2568834C2 (ru) 2015-11-20
CN107412771A (zh) 2017-12-01
WO2011031890A4 (en) 2011-10-13
EP2475362A2 (en) 2012-07-18
TR201905548T4 (tr) 2019-05-21
HUE043387T2 (hu) 2019-08-28
PT2475362T (pt) 2019-05-27
JP2013504587A (ja) 2013-02-07
CY1121973T1 (el) 2020-10-14
AR079000A1 (es) 2011-12-21
JP5710619B2 (ja) 2015-04-30
CN102753164A (zh) 2012-10-24
AU2010292192A1 (en) 2012-03-29
EP2475362B1 (en) 2019-03-27
US20110059186A1 (en) 2011-03-10
BR112012008315A2 (pt) 2016-09-13
KR101721009B1 (ko) 2017-03-29
PL2475362T3 (pl) 2019-09-30
ES2723778T3 (es) 2019-09-02
AU2010292192B2 (en) 2015-04-02
MX2012002855A (es) 2012-07-20
RU2012108144A (ru) 2013-10-20
LT2475362T (lt) 2019-06-10
CA2772411A1 (en) 2011-03-17
WO2011031890A2 (en) 2011-03-17
SG10201608967WA (en) 2016-12-29
EP2475362A4 (en) 2013-03-27
TW201114430A (en) 2011-05-01
CA2772411C (en) 2017-08-22

Similar Documents

Publication Publication Date Title
IL261257B (en) Humanized fc㚚šššššr mice
HRP20170991T1 (hr) Pokretni zasloni i povezani postupci
DK3417701T3 (da) Genmodificerede mus og indpodning
HRP20150557T1 (xx) Acilirani analozi glukagona
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2528625T3 (da) Pyrrolobenzodiazepiner og konjugater deraf
DK2470295T3 (da) Partikelpumpefremgangsmåder og indretninger
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
DK2437830T4 (da) Anordning til lægemiddelleveringsindretning og lægemiddelleveringsindretning
DK3150721T3 (da) Pankreascancermarkører og detekteringsfremgangsmåder
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
BR112012000032A2 (pt) meios terapêuticos e diagnósticos inovadores
DK2086213T3 (da) Billedlæseapparat og billeddannelseapparat
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI1007909A2 (pt) método e dispositivo médico
DK2642992T3 (da) Forbindelser og anvendelse deraf
DK2385954T3 (da) Kompleks og fremstillingsproces
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
PT2519505E (pt) Derivados de 8-hidroxiquinolina-7-carboxamida terciários e suas utilizações